MAIA Biotechnology, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

Stockholders' Equity - Additional Information (Details) - USD ($)				1 Months Ended		2 Months Ended	3 Months Ended					9 Months Ended
	Aug. 03, 2022	Aug. 01, 2022	Aug. 13, 2021	May 31, 2022	Jan. 31, 2022	Feb. 28, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares authorized		70,000,000					70,000,000					70,000,000		30,000,000
Preferred stock, shares authorized		30,000,000					30,000,000					30,000,000		70,000,000
Common stock, par value							$ 0.0001					$ 0.0001		$ 0.0001
Preferred stock, shares issued							0					0		0
Preferred stock, par value							$ 0.0001					$ 0.0001		$ 0.0001
Common stock, shares issued							10,945,904					10,945,904		7,584,980
Number of common stock sold				11,111		263,729
Sale of common stock, price per share				$ 9		$ 9
Common stock per share						$ 9.00
Gross proceeds from sale of common stock	$ 9,100,000			$ 99,999		$ 2,373,561						$ 2,473,560	$ 5,366,170
Warrants exercise price, per share		$ 6.25
Transaction costs				$ 0		$ 0
Stock compensation expense							$ 532,438			$ 778,544		1,830,536	$ 2,108,868
Deemed dividend on warrant modification												$ (450,578)
Warrants exercised, shares				394,501
Cashless exercise at fair market value per share				$ 9
Issuance of common shares upon cashless exercise of warrants, shares				315,601
Stock options outstanding							6,511,910					6,511,910		5,797,185
Fair value assumptions, contractual term												7 years
Exercise price percentage												110.00%
Percentage of shares granted												10.00%
Warrants and rights exercisable period		Jan. 23, 2023
Class of warrant or right date from which warrants or rights expire		Jul. 27, 2027
Black-Sholes Method
Subsidiary or Equity Method Investee [Line Items]
Risk free interest rate	2.82%
Volatility rate	77.50%
Fair value assumptions, contractual term	5 years
Warrants	$ 343,735
January 1 to January 26, 2022 [Member]
Subsidiary or Equity Method Investee [Line Items]
Common stock, par value							$ 8.87					$ 8.87
January 27 to May 31, 2022 [Member]
Subsidiary or Equity Method Investee [Line Items]
Sale of common stock, price per share							9					9
June 1, 2022 to August 1, 2022 [Member]
Subsidiary or Equity Method Investee [Line Items]
Sale of common stock, price per share							$ 5					$ 5
January 1, 2021 to February 28, 2021 [Member]
Subsidiary or Equity Method Investee [Line Items]
Sale of common stock, price per share										$ 1.80			$ 1.80
March 1, 2021 to June 6, 2021 [Member]
Subsidiary or Equity Method Investee [Line Items]
Sale of common stock, price per share										$ 1.83			$ 1.83
Maximum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term												10 years
Warrants to purchase aggregate of common stock		100,000
2018 Stock Option Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance							0					0
Stock options outstanding							1,924,500					1,924,500
Amended and Restated 2020 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance							0					0
Stock options outstanding							3,993,023					3,993,023
2021 Equity Incentive Plan
Subsidiary or Equity Method Investee [Line Items]
Common stock reserved for issuance		1,909,518					1,315,131					1,315,131
Stock options outstanding							594,387					594,387
IPO
Subsidiary or Equity Method Investee [Line Items]
Common stock, shares issued		219,872
Number of common stock sold		2,000,000
Sale of common stock, price per share		$ 5
Deemed dividend declared		$ 1,099,360
Common stock per share		$ 5.00				$ 5.00
Gross proceeds from common stock		$ 10,000,000
Number of warrants exercise		20,520
Warrants exercise price, per share		$ 5.00
Overallotment Option
Subsidiary or Equity Method Investee [Line Items]
Number of common stock sold	300,000
Sale of common stock, price per share	$ 5
Common stock per share	$ 5.00
Gross proceeds from common stock	$ 1,500,000
Overallotment Option \| Maximum
Subsidiary or Equity Method Investee [Line Items]
Class of warrant or right additional purchase aggregate of common stock	15,000
Common Stock
Subsidiary or Equity Method Investee [Line Items]
Number of common stock sold				11,111		263,729
Sale of common stock, price per share				$ 9		$ 9.00
Issuance of restricted common shares, Shares											15,278
Issuance of common shares upon exercise of warrants, Shares				153,000	61,111			468,601	61,111
Proceeds from issuance of common stock upon exercise of warrants				$ 275,400	$ 110,000
Common Stock \| IPO
Subsidiary or Equity Method Investee [Line Items]
Number of common stock sold							2,300,000
Founder
Subsidiary or Equity Method Investee [Line Items]
Stock compensation expense													$ 202,500
Issuance of restricted common shares, Shares													87,500
Restricted Stock Awards
Subsidiary or Equity Method Investee [Line Items]
Founders shares vested												58,333
Unvested shares							0					0		58,333
Restricted Stock Awards \| Founder
Subsidiary or Equity Method Investee [Line Items]
Shares granted													112,500
MAIA Stock Warrants
Subsidiary or Equity Method Investee [Line Items]
Warrant modification, value					$ 144,497
Deemed dividend on warrant modification									$ 450,578
Stock Options
Subsidiary or Equity Method Investee [Line Items]
Weighted-average grant date fair value												$ 3.11	$ 2.57
Unrecognized compensation							$ 3,829,045					$ 3,829,045
Unrecognized compensation expense, recognized period												3 years 4 months 24 days
Stock Options \| Maximum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term												6 years 3 months	6 years 6 months
Stock Options \| Minimum
Subsidiary or Equity Method Investee [Line Items]
Fair value assumptions, contractual term												5 years	5 years
T H I O \| Founder
Subsidiary or Equity Method Investee [Line Items]
Issuance of restricted common shares, Shares			612,500
T H I O \| Restricted Stock Awards \| Founder
Subsidiary or Equity Method Investee [Line Items]
Founders shares vested			612,500
Founders shares cancelled			612,500